Atezolizumab (atezolizumab)
Genentech / Roche (brand: Tecentriq) · PD-L1 Immune Checkpoint Inhibitor
What is Atezolizumab? Atezolizumab is the generic/nonproprietary name for the active ingredient in Tecentriq and Tecentriq Hybreza. It is a PD-L1 immune checkpoint inhibitor used in multiple oncology settings.
About Atezolizumab
| Brand Name | Atezolizumab |
| Generic / INN | atezolizumab |
| Drug Class | PD-L1 Immune Checkpoint Inhibitor |
| Manufacturer | Genentech / Roche (brand: Tecentriq) |
| Administration | Intravenous (IV) infusion |
| FDA Approval | 2016 |
| Presentation | Atezolizumab is available as brand Tecentriq (1200 mg/20 mL vials) and Tecentriq Hybreza (subcutaneous formulation). |
FDA-Approved Uses for Atezolizumab
The following indications are based on FDA approval as of the last review date. Your oncologist will determine appropriate use based on your specific cancer type, stage, biomarker status, and overall treatment plan.
- See Tecentriq for FDA-approved brand indications
- Urothelial carcinoma
- Non-small cell lung cancer
- Small cell lung cancer (combination, extensive-stage)
- Hepatocellular carcinoma
- Melanoma (combination)
- Triple-negative breast cancer (PD-L1 positive)
How Does Atezolizumab Work?
Atezolizumab is an anti-PD-L1 monoclonal antibody that blocks PD-L1 from binding to the PD-1 and B7-1 receptors on T cells. By blocking this inhibitory signal, atezolizumab restores T cell-mediated anti-tumor immunity.
Dosage & Administration
Dosing depends on the specific product (Tecentriq IV vs. Tecentriq Hybreza subcutaneous). For Tecentriq IV: 840 mg Q2W, 1200 mg Q3W, or 1680 mg Q4W.
Dosing for oncology medications is individualized by the treating oncologist or oncology pharmacist. Do not adjust dosing without consulting your healthcare team. The information on this page is educational only and does not replace the official prescribing information or your provider's guidance.
Warnings, Precautions & Side Effects
General Warning
Immune-mediated adverse reactions across multiple organ systems. Infusion-related reactions (IV). Injection site reactions (subcutaneous). Embryo-fetal toxicity.
- Immune-mediated pneumonitis
- Immune-mediated hepatitis
- Immune-mediated colitis
- Immune-mediated endocrinopathies
Common Side Effects
- Fatigue
- Decreased appetite
- Nausea
- Urinary tract infection
- Fever
- Constipation
This is not a complete list. Report any new or worsening symptoms to your oncologist or healthcare provider promptly.
Storage & Handling
Refrigerate at 2°C to 8°C (36°F to 46°F). Do not freeze.
Oncology medications require careful handling. BiologicHealthPlus provides cold-chain specialty delivery with temperature monitoring for medications that require refrigeration. Do not use the medication if the storage chain has been compromised.
Insurance Coverage, Prior Authorization & Patient Assistance
🛡️ Commercial Insurance
Atezolizumab is a specialty oncology medication covered by most major commercial insurance plans when medically necessary and prior authorized. Coverage varies by plan, indication, and formulary tier. BiologicHealthPlus verifies benefits at no cost to patients.
✅ Prior Authorization
Prior authorization is required by virtually all insurance plans for Atezolizumab. Our team handles the full prior authorization process — submitting clinical documentation, peer-to-peer reviews when needed, and appeals — at no cost to patients or providers.
🏥 Medicare & Medicaid
Medicare coverage for oncology medications depends on route of administration. Intravenous oncology medications are typically covered under Medicare Part B (medical benefit) when administered in a clinical setting. Subcutaneous formulations may be covered under Part B or Part D depending on administration circumstances. Medicaid coverage varies by state.
🆓 Patient Assistance Programs
Manufacturer patient assistance programs may be available for eligible uninsured or underinsured patients. BiologicHealthPlus can assess your eligibility and help with the application process. Contact our team for a confidential eligibility review.
Prior Authorization Guide Patient Assistance Programs Insurance & Savings Medication Costs
Frequently Asked Questions About Atezolizumab
Atezolizumab is the generic/nonproprietary name for the active ingredient in Tecentriq (IV) and Tecentriq Hybreza (subcutaneous). It is a PD-L1 immune checkpoint inhibitor used in oncology.
The FDA-approved brand names for atezolizumab are Tecentriq (intravenous) and Tecentriq Hybreza (subcutaneous), both manufactured by Genentech/Roche.
Atezolizumab blocks PD-L1 on tumor cells, preventing tumors from suppressing T cell activity. This allows the immune system to recognize and attack cancer cells more effectively.
Related Medications & Conditions
Related Medications
Tecentriq · Tecentriq Hybreza · Keytruda · Pembrolizumab
Related Conditions
Non-small cell lung cancer · Urothelial carcinoma · Hepatocellular carcinoma